Your Partner in Translational Pharmaceutical Research: From Molecules to Medicines
Recent Media Releases
3D Printing of Oesophageal stents for anticancer drug delivery: UniSA and 7News
US FDA Approval and commercial launch of a Vaginal Contraceptive: UniSA and 7News
Improved Bioavailability of Curcumin: UniSA and 7News
Background
Professor Sanjay Garg is a pharmaceutical scientist with a passion for research and teaching in translational drug development and delivery and a mission to make lives better for our patients. He is the Co-Director of the Centre for Pharmaceutical Innovation (CPI) and leads the Pharmaceutical Innovation and Development Group (PIDG). His interdisciplinary research is based on the... Read more
About me
Your Partner in Translational Pharmaceutical Research: From Molecules to Medicines
Recent Media Releases
3D Printing of Oesophageal stents for anticancer drug delivery: UniSA and 7News
US FDA Approval and commercial launch of a Vaginal Contraceptive: UniSA and 7News
Improved Bioavailability of Curcumin: UniSA and 7News
Background
Professor Sanjay Garg is a pharmaceutical scientist with a passion for research and teaching in translational drug development and delivery and a mission to make lives better for our patients. He is the Co-Director of the Centre for Pharmaceutical Innovation (CPI) and leads the Pharmaceutical Innovation and Development Group (PIDG). His interdisciplinary research is based on the principles of engagement, innovation, translation, and impact.
Prof Garg is a pharmacist and completed PhD from the National Institute of Immunology, India. He joined the Program for Topical Prevention of Conception and Disease (TOPCAD) at Rush University, Chicago (1995-1998) the USA, developing novel microbicides compounds and formulations. Several of his patented formulations have reached clinical stages and market in the USA, India, New Zealand, UK, and Australia, e.g., Acidform (USA Patent 6706276) has been approved by FDA as a non-hormonal contraceptive (Phexxi) and is marketed in the USA. During his tenure with the University of Auckland, New Zealand (2003-2011), he established AnQual Good Laboratory Practice (GLP) compliant analytical laboratory. Acting as Deputy Head of the Auckland Pharmacy School, he played a critical role in establishing research and post-graduate program.
Research Focus
Prof Garg's team at PIDG is focusing on novel anticancer drug delivery systems, nanotechnology, antibacterial compounds and formulations for superbugs, wound healing, and veterinary formulations. He continues to work on cross-disciplinary projects that benefit patients directly.
Research Outputs and Awards
With the research team, Prof Garg has published 243 peer-reviewed papers, forty-four patents, twenty-four book chapters, edited four books, and successfully completed technology transfers for twelve products, leading to h index of 58 (Google Scholar). He has supervised 225 research scholars at all levels, including nine current PhD students
In 2015, Prof Garg was honoured with the Australasian Pharmaceutical Science Association (APSA) Medal. He was a finalist for the Research Impact Awards 2018 at UniSA. Some other awards that he has received include the President's Medal from the South Australian Indian Medical Association (SAIMA), Butland Award for Excellence in Research Supervision, Young Pharmacy Teacher of the Year, and Fellowship of the Indian Pharmaceutical Association.
Collaborations
Prof Garg collaborates with several human and animal pharmaceutical, biotechnological, nutrition, and complementary medicine companies through private and partnership grants. His research has been supported by Govt. agencies, Foundations and Pharmaceutical companies (e.g. Australian Research Council (ARC), National Health and Medical Research Council (NHMRC), Tertiary Education Commission (TEC) New Zealand, Contraception Research and Development Program (CONRAD), USA; International Partnership for Microbicides (IPM), USA, and many others. He regularly reviews grants from ARC, NHMRC, and National agencies from Brazil, the UK, Singapore, Ireland, South Africa, and Hongkong.
He is passionate about international engagement and acts as Co-Director of the China-Australia Centre for Health Science Research (CACHSR), in collaboration with Shandong University, China. Prof Garg has ongoing adjunct appointments with the International Medical University (IMU), Malaysia and the Manipal Academy of Higher Education (MAHE) India. His research collaborations extend to the USA, Canada, Brazil, India, Malaysia, and China, and he is very keen to develop new links, especially research staff and student exchanges for the short or long term.
Research Facilities
Prof Garg's laboratories are in the new 247 million AUD purpose-built Health Innovation Building in the City West Adelaide. The labs are well equipped with small and pilot-scale pharmaceutical development, analysis, and characterization equipment for various dosage forms.
About me
About me
Doctor of Philosophy National Institute of immunology, India
Master of Pharmacy University of Delhi, India
Master of Management University of Auckland, New Zealand
Jan 2012 to present: Professor of Pharmaceutical Sciences, School of Pharmacy and Medical Sciences, and Director, Centre for Cancer Diagnostics and Therapeutics (CCDT), University of South Australia, Adelaide, Australia. Director, China Australia Centre for Health Science Research; Adjunct Professor, School of Pharmacy, International Medical University, Malaysia; JSS college of Pharmacy and Manipal College of Pharmacy, India.
Jun 2003 to Dec 2011: Associate Professor and Deputy Head, School of Pharmacy, University of Auckland; Founder and Chief Scientific Officer, AnQual GLP Laboratories.
Jul 2002 to May 2003 Associate Professor, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India; Assistant Professor from May 1998 to June 2002.
Apr 1995 to Apr 1998 Product Development Research Scientist and Assistant Professor, The Program for Topical Prevention of Conception and Disease (TOPCAD), Section of Ob/Gyn. Research, Rush Presbyterian St. Luke’s Medical Centre, Rush University, Chicago, USA.
Jul 1994 to Mar 1995 Research Associate, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.
Jul 1989 to Jul 1990 Product Executive with a Pharmaceutical Company, New Delhi, India.
Research
Excludes commercial-in-confidence projects.
Development of the Second-Generation Amphora Formulations, EVOFEM Biosciences, 03/02/2020 - 30/06/2022
Stability studies of Omeprazole, Luoda Pharma Pty Ltd, 20/07/2020 - 20/04/2021
FIA056 - Ind Ptnr - Development of a novel and innovative melatonin film for treatment of insomnia, Green Dispensary Pty Ltd, 01/02/2020 - 30/11/2020
FIA038 Ind Ptnr - Development of a Novel Taste Masked Oral Antimicrobial Preparation for Aquaculture, Clean Seas Seafood Limited, 07/02/2019 - 31/05/2020
Stability Evaluation of Extemporaneously Compounded Oral Flecainide, Pharmac, 18/07/2019 - 06/12/2019
Drug targeting to immune cells using modified inulin particles, ARC - Linkage Project, 05/05/2015 - 30/06/2019
An Extraction Method Development for Tilmicosin in Tilmovet, SunPork Solutions, 16/04/2018 - 31/05/2018
Pharmaceutical product development of a range of new compounds and existing drugs for human and veterinary applications, Luoda Pharma Pty Ltd, 06/04/2015 - 06/04/2018
Pharmaceutical Development of a novel carbohydrate compound, Sirtex Technologies Pty Ltd, 20/11/2015 - 30/09/2016
Development of novel vaginal microbicide tablets for an anti-HIV compound DS003, International Partnership for Microbicides, Inc., 15/08/2013 - 30/03/2016
Stability evaluation of extemporaneously compounded tacrolimus formulation, Pharmac, 25/09/2013 - 28/05/2015
SAXS and XRD characterisation of docetaxal containing polymeric films, Research Projects (Formerly AINSE Awards and Research Fellowships), 01/08/2014 - 15/03/2015
Development of novel antimicrobial compounds and formulations, Luoda Pharma Pty Ltd, 01/03/2013 - 01/03/2015
Penicillin antibiotic drug stability in syringes for the purposes of skin testing in drug allergy, Women's and Children's Hospital Foundation, 01/01/2013 - 01/07/2014
Establishing the evidence to ensure quality, safety, and effectiveness of the extemporaneously compounded formulations, Women's and Children's Hospital Foundation, 01/01/2013 - 01/07/2014
Research
Research outputs for the last seven years are shown below. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2018 |
Open access
22
18
5
|
2017 |
Open access
26
26
1
|
2017 |
Open access
12
11
|
2016 |
Open access
6
2
|
2016 |
17
16
1
|
Year | Output |
---|---|
2021 |
2
|
2021 |
|
2018 |
Open access
|
2018 |
Open access
|
2013 |
6
3
|
2010 |
|
2008 |
|
Year | Output |
---|---|
2022 |
Open access
|
2022 |
1
1
5
|
2022 |
1
1
5
|
2022 |
2
2
|
2022 |
|
2022 |
Open access
|
2022 |
Open access
|
2022 |
Open access
|
2022 |
Open access
|
2022 |
Open access
1
|
2022 |
Open access
|
2021 |
Open access
2
2
3
|
2021 |
Open access
8
7
2
|
2021 |
Open access
5
5
2
|
2021 |
Open access
|
2021 |
Open access
4
4
|
2021 |
Open access
4
2
|
2021 |
Open access
2
1
10
|
2021 |
Open access
3
3
|
2021 |
8
8
6
|
2021 |
Open access
9
8
44
|
2021 |
Open access
19
17
38
|
2021 |
Open access
21
21
3
|
2021 |
Open access
4
3
1
|
2021 |
Open access
3
3
2
|
2021 |
Open access
11
11
838
|
2021 |
Open access
4
|
2021 |
Open access
5
2
|
2021 |
Open access
6
|
2021 |
5
5
1
|
2021 |
32
27
|
2020 |
Open access
5
4
|
2020 |
Open access
|
2020 |
Open access
23
23
2
|
2020 |
Open access
4
4
1
|
2020 |
Open access
13
12
100
|
2020 |
Open access
13
14
|
2020 |
Open access
6
|
2020 |
Open access
35
36
4
|
2020 |
Open access
1
|
2020 |
Open access
4
4
4
|
2020 |
14
11
|
2020 |
Open access
7
7
4
|
2020 |
Open access
22
32
|
2020 |
Open access
1
1
|
2020 |
Open access
20
19
131
|
2019 |
Open access
8
8
2
|
2019 |
Open access
8
8
1
|
2019 |
Open access
28
22
|
2019 |
Open access
24
21
|
2019 |
Open access
14
14
1
|
2019 |
Open access
129
112
3
|
2019 |
14
10
11
|
2019 |
Open access
14
16
1
|
2019 |
Open access
11
11
4
|
2019 |
Open access
9
9
2
|
2019 |
Open access
10
10
1
|
2019 |
Open access
12
11
3
|
2018 |
Open access
27
21
|
2018 |
Open access
8
8
5
|
2018 |
Open access
12
12
1
|
2018 |
25
23
|
2018 |
Open access
87
87
1
|
2018 |
1
1
1
|
2018 |
Open access
3
4
1
|
2018 |
10
9
|
2018 |
Open access
370
351
2
|
2018 |
Open access
16
18
3
|
2018 |
Open access
12
10
|
2018 |
24
20
88
|
2018 |
23
21
81
|
2018 |
Open access
13
12
4
|
2018 |
3
3
|
2018 |
Open access
2
4
5
|
2018 |
Open access
22
18
5
|
2017 |
2
2
|
2017 |
Open access
9
12
|
2017 |
Open access
1
1
1
|
2017 |
Open access
9
8
|
2017 |
Open access
6
7
1
|
2017 |
Open access
92
83
|
2017 |
Open access
26
26
1
|
2017 |
Open access
25
23
6
|
2017 |
Open access
19
19
6
|
2017 |
Open access
8
8
|
2017 |
Open access
16
17
7
|
2017 |
Open access
13
13
|
2017 |
Open access
12
11
|
2017 |
Open access
9
8
|
2016 |
Open access
26
25
|
2016 |
Open access
68
56
|
2016 |
Open access
6
2
|
2016 |
Open access
6
6
1
|
2016 |
Open access
62
60
|
2016 |
55
53
1
|
2016 |
17
16
1
|
2015 |
1
1
1
|
2015 |
Open access
79
68
5
|
2015 |
Open access
3
8
|
2015 |
Open access
33
31
|
2015 |
30
27
|
2015 |
18
18
6
|
2015 |
Open access
6
6
|
2015 |
Open access
18
18
5
|
2015 |
Open access
17
17
|
2014 |
3
4
|
2014 |
4
2
1
|
2013 |
7
1
|
2013 |
Open access
2
2
|
2013 |
17
13
1
|
2013 |
25
24
6
|
2013 |
45
35
6
|
2013 |
2
2
|
2013 |
17
19
13
|
2013 |
3
3
|
2013 |
8
9
|
2013 |
Open access
14
13
5
|
2013 |
Open access
58
50
1
|
2013 |
Open access
41
37
1
|
2013 |
Open access
6
6
1
|
2013 |
30
27
3
|
2013 |
85
85
|
2013 |
24
|
2013 |
28
24
6
|
2013 |
7
7
|
2012 |
15
13
|
2012 |
5
3
|
2012 |
15
15
|
2012 |
Open access
28
24
|
2012 |
9
6
|
2012 |
20
19
|
2012 |
27
24
|
2012 |
2
3
|
2012 |
1
1
|
2012 |
|
2012 |
Open access
11
|
2012 |
26
21
6
|
2012 |
20
21
|
2011 |
6
6
|
2011 |
10
10
|
2011 |
8
4
|
2011 |
6
6
|
2011 |
3
1
|
2011 |
Open access
28
25
|
2011 |
47
47
|
2011 |
Open access
10
9
|
2011 |
3
1
|
2011 |
82
83
|
2010 |
30
28
|
2010 |
90
86
|
2010 |
12
10
|
2010 |
3
|
2010 |
137
126
|
2010 |
322
311
|
2010 |
39
40
|
2010 |
32
35
|
2009 |
100
94
|
2009 |
6
|
2009 |
8
6
|
2009 |
106
92
|
2009 |
48
42
|
2008 |
19
17
|
2008 |
6
6
|
2008 |
Open access
30
39
|
2008 |
5
5
|
2008 |
62
56
|
2008 |
|
2008 |
34
31
|
Year | Output |
---|---|
2009 |
Open access
9
1
|
2008 |
|
PATENTS
Zhou SF, Parikh A, Garg S. Novel pharmaceutical oral formulation of Edaravone drug. Provisional Chinese Application, filed on March 16. 2016;SPI160526-53.
Page S, Garg S, Keenan M, McCluskey A, Stevens A. Compounds and Methods of Treating Infections. Country applications. 2016;Filed as 2014262129 and 2013901516 Australia; BR112015027704-7 Brazil; 2,910,756 Canada; NP entry of PCT/AU2014/000483 China; 14791590.4 Europe; 3871/KOLNP/2015 India; NP entry of PCT/AU2014/000483 Japan; 713621 New Zealand; 2015150264 Russian Federation; 14/888,306 USA; PCT/AU2014/000483 PCT; .
Page S, Garg S. Methods of treating bacterial infections. Country applications. 2016;Filed as 2014262127 and 2013901517 Australia; BR112015027699-7 Brazil; 2,910,752 Canada; NP entry of PCT/AU2014/000480 China; 14791748.8 Europe; 3870/KOLNP/2015 India; NP entry of PCT/AU2014/000480 Japan; 713615 New Zealand; 2015150263 Russian Federation; 14/888,289 USA; PCT/AU2014/000460 PCT.
Page S, Garg S, Keenan M, McCluskey A, Stevens A. Compounds and Methods of Treating Infections. PCT International Patent Application, Filed on May 01. 2014;PCT/AU2014/000483.
Garg S, Zaneveld L, Anderson RA, Waller DP. Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa. USA Patent 6706276. 2004;Mar 16.
Research
Research
Details | Registry | Status |
---|---|---|
A process for the preparation of a rapidly disintegrating bioadhesive pharmaceutical composition Garg, Sanjay; Vermani, Kavita; Kohli, Gunjan; Raghupathi, Kandrapu; Tambwekar, Kastubh; Kaul, Chaman Lal |
IN | Granted |
Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa Garg, Sanjay; Zaneveld, Lourens Jan Dirk; Anderson Jr., Robert Anthony; Waller, Donald Paul |
CA | Granted |
Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa Garg, Sanjay; Zaneveld, Lourens Jan Dirk; Anderson Jr., Robert Anthony; Waller, Donald Paul |
CN | Granted |
Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa Garg, Sanjay; Zaneveld, Lourens Jan Dirk; Anderson Jr., Robert Anthony; Waller, Donald Paul |
EP | Filed |
Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa Garg, Sanjay; Zaneveld, Lourens Jan Dirk; Anderson Jr., Robert Anthony; Waller, Donald Paul |
US | Granted |
Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa Garg, Sanjay; Zaneveld, Lourens Jan Dirk; Anderson Jr., Robert Anthony; Waller, Donald Paul |
WO | Filed |
Compounds and methods of treating infections Page, Stephen; Garg, Sanjay; Keenan, Martine; McCluskey, Adam; Stevens, Andrew |
CA | Filed |
Compounds and methods of treating infections Page, Stephen; Garg, Sanjay; Keenan, Martine; McCluskey, Adam; Stevens, Andrew |
EP | Filed |
Compounds and methods of treating infections Page, Stephen; Garg, Sanjay; Keenan, Martine; McCluskey, Adam; Stevens, Andrew |
US | Filed |
Compounds and methods of treating infections Page, Stephen; Garg, Sanjay; Keenan, Martine; McCluskey, Adam; Stevens, Andrew |
WO | Filed |
Zhou, Xinfu; Parikh, Ankit; Garg, Sanjay |
CN | Filed |
Zhou, Xinfu; Parikh, Ankit; Garg, Sanjay |
WO | Filed |
Methods for treating bacterial infections Page, Stephen; Garg, Sanjay |
US | Granted |
Methods of treating microbial infections, including Mastitis Page, Stephen; Garg, Sanjay |
CA | Filed |
Methods of treating microbial infections, including Mastitis Page, Stephen; Garg, Sanjay |
EP | Filed |
Methods of treating microbial infections, including Mastitis Page, Stephen; Garg, Sanjay |
US | Filed |
Methods of treating microbial infections, including Mastitis Page, Stephen; Garg, Sanjay |
WO | Filed |
Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient Garg, Sanjay; Verma, Rajan Kumar; Kaul, Chaman Lal |
EP | Filed |
Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient Garg, Sanjay; Verma, Rajan Kumar; Kaul, Chaman Lal |
KR | Granted |
Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient Garg, Sanjay; Verma, Rajan Kumar; Kaul, Chaman Lal |
US | Filed |
Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient Garg, Sanjay; Verma, Rajan Kumar; Kaul, Chaman Lal |
WO | Filed |
Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient Garg, Sanjay; Verma, Rajan Kumar; Kaul, Chaman Lal |
ZA | Filed |
External engagement & recognition
Organisation | Country |
---|---|
Advanced Veterinary Therapeutics | AUSTRALIA |
Ancare Scientific Ltd | NEW ZEALAND |
ANSTO | AUSTRALIA |
Army Medical University | PAKISTAN |
Asure Quality | NEW ZEALAND |
Auckland City Hospital | NEW ZEALAND |
Australian Nuclear Science and Technology Organisation | AUSTRALIA |
Bioactives Research New Zealand | NEW ZEALAND |
Chalmers University of Technology | SWEDEN |
Changchun University | CHINA |
Chuulangun Aboriginal Corporation | AUSTRALIA |
CONRAD | UNITED STATES |
Deakin University | AUSTRALIA |
Department of Pharmaceutical Sciences, School of Pharmacy | UNITED STATES |
Dermatology for Animals | AUSTRALIA |
DPT Laboratories | UNITED STATES |
Flinders University | AUSTRALIA |
Gomal University | PAKISTAN |
Government Medical College & Hospital | INDIA |
Griffith University | AUSTRALIA |
Indian Institute of Science | INDIA |
Indian Institute of Science Bangalore | INDIA |
International Medical University | MALAYSIA |
International Partnership for Microbicides | UNITED STATES |
Jamia Hamdard | INDIA |
Jamia Hamdard University | INDIA |
Jilin University | CHINA |
Kunming Medical University | CHINA |
Luoda Pharma Pty Ltd | AUSTRALIA |
Macquarie University | AUSTRALIA |
Magee Women’s Research Institute | UNITED STATES |
Manipal Academy Of Higher Education | INDIA |
Manipal College of Pharmaceutical Sciences | INDIA |
Manipal University | INDIA |
Massey University | NEW ZEALAND |
McGowan Institute for Regenerative Medicine | UNITED STATES |
McMaster University | CANADA |
MedCrystal Forms | UNITED STATES |
Microbial Screening Technologies Pty Ltd | AUSTRALIA |
Micromyx | UNITED STATES |
Middlemore Hospital - National Burn Centre | NEW ZEALAND |
Monash University | AUSTRALIA |
Murdoch University | AUSTRALIA |
National Institute of Pharmaceutical Education and Research (NISER) | INDIA |
National Institute of Technology Karnataka | INDIA |
Nemucore Medical Innovations, Inc | UNITED STATES |
Neoculi Pty Ltd | AUSTRALIA |
Neoculi Pty. Ltd. | AUSTRALIA |
NIRMA University | INDIA |
North-Eastern University | THAILAND |
Pandit Ravishankar Shukla University | INDIA |
Panjab University | INDIA |
Postgraduate Institute of Medical Education and Research | INDIA |
Private Individual | AUSTRALIA |
Punjabi University | INDIA |
Queen Elizabeth Hospital | AUSTRALIA |
SA Health | AUSTRALIA |
Sao Paulo State University | BRAZIL |
Second Affiliated Hospital of Kunming Medical University | CHINA |
Seoul National University | KOREA, REPUBLIC OF (SOUTH) |
Shandong Provincial Qianfoshan Hospital | CHINA |
Shandong University | CHINA |
South Australian Health and Medical Research Institute (SAHMRI) | AUSTRALIA |
Springer Healthcare | NEW ZEALAND |
SunPork Group | AUSTRALIA |
Texas A and M University | UNITED STATES |
Universidade Estadual Paulista | BRAZIL |
University of Adelaide | AUSTRALIA |
University of Auckland | NEW ZEALAND |
University of Canberra | AUSTRALIA |
University of Delhi | INDIA |
University of Newcastle | AUSTRALIA |
University of Otago | NEW ZEALAND |
University of Queensland | AUSTRALIA |
University of Sao Paulo | BRAZIL |
University of South Australia | AUSTRALIA |
University of South Florida | UNITED STATES |
University of Sydney | AUSTRALIA |
University of Tasmania | AUSTRALIA |
University of Veterinary and Animal Sciences, Lahore | PAKISTAN |
Vaxine | UNITED STATES |
Vaxine Pty Ltd | AUSTRALIA |
Victoria University of Wellington | NEW ZEALAND |
Vietnam National University of Agriculture | VIET NAM |
Women's and Children's Hospital | AUSTRALIA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
Associate EditorBioanalysis |
2018 |
Associate EditorJournal of Basic and Applied Pharmaceutical Sciences |
2018 |
EditorPharmaceutics, BioMed Research International |
2018 |
Editorial Board MemberDrug Design Development and Therapy |
2018 |
Editorial Board MemberPharmaceutical Technology North America |
2018 |
FellowIndian Pharmaceutical Association (IPA), India |
2018 |
MemberProject Management Institute, USA |
2018 |
Regional Editor OceaniaCurrent Pharmaceutical Analysis |
2018 |
Scientific Advisory Committee MemberAustralasian Pharmaceutical Science Association (APSA) |
2018 |
AdjunctInternational Medical University (IMU), Malaysia |
2017 |
AdjunctManipal University, India |
2017 |
Associate EditorBioanalysis |
2017 |
Associate EditorJournal of Basic and Applied Pharmaceutical Sciences |
2017 |
Co-DirectorChina-Australia Centre for Health Science Research (CACHSR) |
2017 |
EditorPharmaceutics, BioMed Research International |
2017 |
Editorial Board MemberDrug Design Development and Therapy |
2017 |
Editorial Board MemberPharmaceutical Technology North America |
2017 |
FellowIndian Pharmaceutical Association (IPA), India |
2017 |
MemberProject Management Institute, USA |
2017 |
Regional Editor OceaniaCurrent Pharmaceutical Analysis |
2017 |
Scientific Advisory Committee MemberAustralasian Pharmaceutical Science Association (APSA) |
2017 |
APSA MedalAustralasian Pharmaceutical Science Association (APSA) |
2015 |
Director, Board Member and Chair, Students Affairs CommitteeInternational Society of Pharmaceutical Engineering (ISPE), Australasia |
2014 |
Executive Committee MemberAustralasian Pharmaceutical Science Association (APSA) |
2014 |
Director, Board Member and Chair, Students Affairs CommitteeInternational Society of Pharmaceutical Engineering (ISPE), Australasia |
2013 |
Executive Committee MemberAustralasian Pharmaceutical Science Association (APSA) |
2013 |
Director, Board Member and Chair, Students Affairs CommitteeInternational Society of Pharmaceutical Engineering (ISPE), Australasia |
2012 |
Executive Committee MemberAustralasian Pharmaceutical Science Association (APSA) |
2012 |
Director, Board Member and Chair, Students Affairs CommitteeInternational Society of Pharmaceutical Engineering (ISPE), Australasia |
2011 |
Executive Committee MemberAustralasian Pharmaceutical Science Association (APSA) |
2011 |
Director, Board Member and Chair, Students Affairs CommitteeInternational Society of Pharmaceutical Engineering (ISPE), Australasia |
2010 |
Executive Committee MemberAustralasian Pharmaceutical Science Association (APSA) |
2010 |
Teaching & student supervision
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
3D Printed Biodegradable Films for Targeted Chemotherapy in Liver Cancer | Current |
Decorated cubosomes for anti-cancer drugs delivery and targeting | Current |
Development of 3D printed patient-centric cannabidiol and estrogen films: a move towards personalised medicine | Current |
Development of novel delivery system for immune checkpoint inhibitors using 3D printed microneedle patches for melanoma | Current |
Discovering the Roles of Orexins in Parkinson's disease | Current |
Evaluation of the role of pH in wound healing and development of buffered preparations to promote regeneration | Current |
Novel antimicrobials delivery systems for multi drug resistant infections | Current |
Re-positioning of existing drugs as antimicrobial agents for resistant infections. | Current |
Targeting BMP signalling for enhancing growth plate regeneration | Current |
Targeting ovarian cancer with nanoparticle drug carriers using G protein-coupled receptors as molecular entry sites | Current |
Characterisation of lipopolysaccharide models of Parkinson’s disease, and the effects of edaravone and curcumin | Completed |
Development of combined therapy for Alzheimer’s disease: a mechanistic study | Completed |
Development of drug-eluting stents for the localised delivery of 5-fluorouracil targeted towards the treatment of gastrointestinal cancers | Completed |
Development of drug-eluting stents using dip-coating and 3D printing techniques for the localised treatment of oesophageal cancer | Completed |
Development of localized stent drug delivery system for esophageal cancer | Completed |
Development of monocyte targeted delivery system for doxorubicin using modified inulin particles | Completed |
Development of novel dosage forms to repurpose the drugs for Alzheimer's disease | Completed |
Evaluation of drug transfer in human breast milk | Completed |
Intracellular and localized drug delivery using inulin | Completed |
Novel functionalized mesoporous silica nanoparticles as targeted delivery systems to estrogen receptor-overexpressing breast cancer | Completed |
Stimuli-responsive silver nanoparticles delivery system for infected wounds | Completed |
Targeting prostate cancer cells with elastin like peptide based micelles displaying gastrin releasing peptide | Completed |
Three-dimensional printing of biodegradable polymeric scaffold for cancer therapy | Completed |